NorthCrest Asset Manangement’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.14M Buy
25,857
+845
+3% +$162K 0.13% 140
2026
Q1
$4.44M Sell
25,012
-8,775
-26% -$1.62M 0.14% 139
2025
Q4
$5.9M Buy
33,787
+1,151
+4% +$188K 0.13% 133
2025
Q3
$4.97M Sell
32,636
-33
-0.1% -$4.46K 0.12% 145
2025
Q2
$4.34M Sell
32,669
-1,863
-5% -$232K 0.12% 150
2025
Q1
$4.73M Buy
34,532
+2,126
+7% +$304K 0.14% 143
2024
Q4
$4.96M Buy
32,406
+548
+2% +$92.4K 0.15% 134
2024
Q3
$6.18M Buy
31,858
+386
+1% +$80.8K 0.19% 125
2024
Q2
$7.3M Buy
31,472
+38
+0.1% +$8.26K 0.24% 112
2024
Q1
$6.78M Buy
31,434
+365
+1% +$85.5K 0.23% 118
2023
Q4
$8.04M Sell
31,069
-930
-3% -$228K 0.3% 100
2023
Q3
$8.22M Buy
31,999
+608
+2% +$163K 0.34% 94
2023
Q2
$8.94M Sell
31,391
-155
-0.5% -$46.1K 0.35% 92
2023
Q1
$8.77M Sell
31,546
-77
-0.2% -$21.3K 0.37% 92
2022
Q4
$8.76M Sell
31,623
-928
-3% -$262K 0.5% 71
2022
Q3
$8.69M Sell
32,551
-117
-0.4% -$24.8K 0.47% 80
2022
Q2
$6.66M Buy
32,668
+499
+2% +$102K 0.34% 103
2022
Q1
$6.78M Buy
32,169
+6,196
+24% +$1.35M 0.32% 107
2021
Q4
$6.23M Buy
+25,973
New +$6.68M 0.34% 93

Other funds holding BIIB

NorthCrest Asset Manangement's BIIB Position: Q2 2026 in Review

NorthCrest Asset Manangement increased its Biogen (BIIB) stake by 3.4% in Q2 2026, buying an estimated $162K and bringing the position to 25,857 shares worth $5.14M. The position accounts for 0.13% of the portfolio, ranked #140.

NorthCrest Asset Manangement first reported a position in BIIB in Q4 2021 and has held it in 19 quarters since. The position peaked at $8.94M in Q2 2023. 131 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • NorthCrest Asset Manangement held 25,857 shares of Biogen worth $5.14M as of Q2 2026.
  • NorthCrest Asset Manangement bought 845 Biogen shares in Q2 2026, an estimated $162K.
  • Biogen made up 0.13% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #140 holding.
  • NorthCrest Asset Manangement first reported a position in Biogen in Q4 2021 and has held it in 19 quarters since.
  • NorthCrest Asset Manangement's Biogen position peaked at $8.94M in Q2 2023.
  • 131 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.